Search results
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Zacks via Yahoo Finance· 1 year agoSanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat...
Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars
Investor's Business Daily· 1 year agoSanofi and Regeneron Pharmaceuticals' asthma drug Dupixent succeeded in a final-phase study of...
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Investor's Business Daily· 5 months agoRegeneron Pharmaceuticals and Sanofi said Monday their blockbuster drug, Dupixent, significantly...
Stock-Split Watch: Could These 2 Market-Beaters Be Next?
Motley Fool via Yahoo Finance· 3 months agoFor moves that don't improve the underlying strength of a company's business, stock splits garner a...
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
Motley Fool via Yahoo Finance· 3 months agoThe stock market has given investors plenty to talk about over the last few years, and those who have stayed in it through the ups and downs have dealt...
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
Investor's Business Daily· 3 months agoSanofi stock undercut its 50-day line Thursday despite Dupixent outperformance as its earnings...
Sanofi Raises Profit Guide And Reverses A Drug-Pricing Pitfall
Investor's Business Daily· 2 years agoSanofi stock ended flat Thursday — reversing earlier declines — despite lifting its profit guidance...
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
Investor's Business Daily· 2 years agoAbbVie could soon pressure Regeneron Pharmaceuticals in eczema treatment, an analyst said Friday as...
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Investor's Business Daily· 1 year agoRegeneron stock surged Friday on stronger-than-expected metrics, though its partner Sanofi posted a...
Sanofi Hikes Its Profit Outlook Despite Hefty $1.6 Billion Write-Down
Investor's Business Daily· 2 years agoSanofi stock popped Friday after the French pharma giant hiked its 2022 earnings outlook following a...